| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
CS-722 Free base targets sodium and calcium channels in the central nervous system. By inhibiting both sodium and calcium currents, it suppresses spontaneous inhibitory and excitatory postsynaptic currents in hippocampal cultures. This mechanism is consistent with its centrally acting muscle relaxant activity and its depressant effects on spinal reflexes.
|
|---|---|
| ln Vitro |
In vitro, CS-722 Free base inhibits spontaneous inhibitory postsynaptic currents and excitatory postsynaptic currents in hippocampal cultures. This inhibition is likely mediated through the inhibition of both sodium and calcium currents. Its in vitro activities are characteristic of centrally acting muscle relaxants.
|
| ln Vivo |
In vivo, CS-722 Free base exhibits muscle relaxant activity and depressant effects on the spinal reflex. As a centrally acting muscle relaxant, it reduces muscle tone and inhibits spinal reflexes without affecting peripheral neuromuscular transmission. Its effects are mediated through its actions on sodium and calcium channels in the central nervous system.
|
| Enzyme Assay |
In vitro electrophysiological assays for CS-722 Free base are conducted using hippocampal cultures. Whole-cell patch-clamp recordings are performed to measure spontaneous inhibitory postsynaptic currents (sIPSCs) and excitatory postsynaptic currents (sEPSCs). The compound is applied at varying concentrations, and the frequency and amplitude of synaptic currents are measured before and after compound application.
|
| Cell Assay |
Cellular assays for CS-722 Free base are performed using neuronal cell lines or primary hippocampal neurons. Cells are treated with compound concentrations ranging from 0.1 to 100 µM. Sodium and calcium currents are measured using patch-clamp electrophysiology. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal studies for CS-722 Free base are conducted in rodent models to evaluate its muscle relaxant activity. The compound is administered orally or intraperitoneally. Muscle relaxant effects are assessed using tests such as the rotarod test, grip strength test, or by measuring the inhibition of spinal reflexes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CS-722 Free base are not well characterized. Standard PK studies in rodents would be required to determine absorption, distribution, metabolism, and excretion parameters.
|
| Toxicity/Toxicokinetics |
Toxicological data for CS-722 Free base are limited. As a research compound, it is designated for laboratory use only. Standard toxicity screening would involve acute and repeated-dose studies in rodents.
|
| References |
|
| Additional Infomation |
CS-722 Free base is a centrally acting muscle relaxant that inhibits sodium and calcium currents. It suppresses synaptic currents in hippocampal cultures. It is not clinically approved.
|
| Molecular Formula |
C16H19CLN2O4
|
|---|---|
| Molecular Weight |
338.79
|
| Exact Mass |
338.103
|
| CAS # |
749179-13-3
|
| PubChem CID |
132660
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
459
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1COCCN1C[C@H](CN2C(=O)C(=C(O2)C3=CC=CC=C3)Cl)O
|
| InChi Key |
NINUODAOHUBAAQ-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C16H19ClN2O4/c17-14-15(12-4-2-1-3-5-12)23-19(16(14)21)11-13(20)10-18-6-8-22-9-7-18/h1-5,13,20H,6-11H2/t13-/m1/s1
|
| Chemical Name |
4-chloro-2-[(2R)-2-hydroxy-3-morpholin-4-ylpropyl]-5-phenyl-1,2-oxazol-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9517 mL | 14.7584 mL | 29.5168 mL | |
| 5 mM | 0.5903 mL | 2.9517 mL | 5.9034 mL | |
| 10 mM | 0.2952 mL | 1.4758 mL | 2.9517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
